Breast cancer is one of the most common malignant diseases in women. Triplenegative breast cancer (TNBC) shows higher aggressiveness and recurrence rates than other subtypes, and there are no effective targets or tailored treatments for TNBC patients. Thus, finding effective prognostic markers for TNBC could help clinicians in their ability to care for their patients. We used tissue microarrays (TMAs) to detect microRNA-493 (miR-493) expression in breast cancer samples. A miR-CURY LNA detection probe specific for miR-493 was used in in situ hybridization assays. Staining results were reviewed by two independent pathologists and classified as high or low expression of miR-493. Kaplan-Meier survival plots and multivariate Cox analysis were carried out to clarify the relationship between miR-493 and survival. In the Kaplan-Meier analysis, patients with high miR-493 expression had better disease-free survival than patients with low miR-493 expression. After adjusting for common clinicopathological factors in breast cancer, the expression level of miR-493 was still a significant prognostic factor in breast cancer. Further subtype analysis revealed that miR-493 expression levels were only significantly prognostic in TNBC patients. These results were validated in the Molecular Taxonomy of Breast Cancer International Consortium database for overall survival. We proved the prognostic role of miR-493 in TNBC by using one of the largest breast cancer TMAs available and validated it in a large public RNA sequencing database.
in triple-negative breast cancer (TNBC; estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor receptor 2 [HER2]-negative), which usually shows higher aggressiveness and recurrence rates and is widely accepted as a heterogeneous disease. For TNBC patients, there are no effective targets or tailored treatments. The standard adjuvant treatment for TNBC is chemotherapy, the doses and regimens of which can be modified according to the patient's risk of recurrence. Thus, finding effective prognostic markers for TNBC might help clinicians in their ability to take better care of their patients. 11, 12 MicroRNA (miRNA) are small non-coding elements, usually 21-25 nt in length, which regulate expression of various genes and some important cellular processes. 13, 14 The role of miRNAs in breast cancer has been widely studied. [15] [16] [17] [18] There are oncogenic miRNAs, like miR-21, 15 ,16 miR-155, 17, 18 miR-10b, 19, 20 and miR27a, 21, 22 which are frequently upregulated in breast cancer and influence tumor cell survival, promote proliferation and metastasis, and inhibit cell death.
There are also tumor-suppressive miRNAs, like the let-7 family, 23, 24 the miR-200 family, 25, 26 miR-145, 27 and miR-205, 28, 29 which are significantly downregulated in breast cancer and can silence different target genes, and negatively regulate epithelial-mesenchymal transition and tumor development.
MicroRNA-493 has been explored in cancer in previous studies.
According to these studies, the roles of miR-493 in cancer are mainly suppressive. In lung cancer, Gu et al 30 Several studies have shown that miRNAs can be prognostic factors in breast cancer. 13, 35, 36 In the present study, we focused on miR-493, and have used our center's well-developed tissue microarray (TMA) to explore its prognostic value in breast cancer, especially in TNBC.
| MATERIALS AND METHODS

| Study cohort
We used our prepared TMAs, which have been described previously, [35] [36] [37] [38] 
| In situ hybridization of miR-493
All staining was undertaken on the well-developed TMAs. The detailed method used in the development of the TMAs has been described previously. [35] [36] [37] [38] A miRCURY LNA detection probe specific between the two pathologists, a third pathologist would be consulted.
The SI was derived by multiplying the two results mentioned above.
Samples with SIs >4 were considered as miR-493 high expression. Examples of high and low expression stains are shown in Figure 1(A) . classifying its expression as high or low, was retrieved by using the auto select best cut-off function in miRpower in the whole available METABRIC breast cancer cohort, and applied it to subtype analyses. 
| Statistical analysis
| RESULTS
Detailed information of miR-493 expression with different clinicopathological factors is listed in Table 1 . Among 384 patients, 116
patients (30.1%) were classified as having high miR-493 expression. There was no statistically significant difference in miR-493 expression among any of the clinicopathological factors studied (Table 1 ).
In the Kaplan-Meier analysis, patients with high miR-493 expression had better DFS than patients with low miR-493 expression (Figure 1B ; log-rank, P = .008). Although there was no distribution difference of miR-493 expression level with the studied clinicopathological factors, we still undertook multivariate analysis using a Cox proportional hazards regression model to rule out potential confounders. As shown in Table 2 , after adjusting for the common clinicopathological factors in breast cancer, the expression level of miR-493 was still a significant prognostic factor in breast cancer. Micro-RNA-493 high-expression patients have less risk of disease recurrence compared with low-expression patients (HR = 0.51; 95% CI, 0.28-0.92; P = .026). Other significant factors were lymph node status and HER2 status ( Table 2) .
To further explore miR-493 prognostic value in breast cancer, To validate our finding of the prognostic effect of miR-493 in breast cancer, we downloaded miR-493 expression data from the METABRIC database using miRpower. In the whole breast cancer cohort, the difference in expression level of miR-493, the cut-off for which was determined by miRpower automatically, was not significantly related with OS in patients ( Figure 3A ; P = .162). In detailed subtype analyses, we found the same prognostic value of miR-493 in TNBC patients; that is, patients with high miR-493 expression level would have better OS than those with low-level expression ( Figure 3B ; P = .048). In the HER2-positive group, high expression of miR-493 was also correlated with better OS (Figure 3E ; P = .05); however, only 80 patients were available for this 
| DISCUSSION
In the present study, we found that miR-493 could be a prognostic factor in breast cancer, especially in the TNBC subtype. Patients with high miR-493 expression had better survival outcomes compared with patients with low expression. Further analysis in the different subtypes showed that the prognostic value of miR-493 was included miR-155, miR-493, miR-30e, and miR-27a, which allowed subdivision of TNBCs into high-and low-risk groups. They proved that this subclassification was a powerful diagnostic and prognostic biomarker in TNBCs. Taken together with our study, these results proved that miR-493 could be an important tumor suppressor and prognostic marker in breast cancer.
Our study had some limitations. First, this was a retrospective analysis in a relatively small patient cohort. More samples will be needed to further validate the prognostic value of miR-493. Second, determining miR-493 expression levels using TMAs in breast cancer might be subjective, even though we used two independent pathologists who were blinded to patients' survival outcomes and consulted a third pathologist to resolve any discord. Use of the METABRIC database in the validation of the results might help in attenuating these limitations.
Taken together, by using one of the largest breast cancer TMAs available in conjunction with a large public RNA sequencing database, we have shown that miR-493 can be used as a prognostic marker in TNBC. Clarifying the mechanism by which miR-493 plays a tumor-suppressor role in breast cancer will require additional functional studies.
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